Global Infectious Diseases Partnering 2012-2018: Deal Trends, Players and Financials from Agreements by the World’s Leading Pharma and Biotech Companies

Dublin, March 07, 2018 (GLOBE NEWSWIRE) -- The "Global Infectious Diseases Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Global Infectious Diseases Partnering 2012 to 2018 provides the full collection of Infectious Diseases disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals.

The report presents financial deal terms values for Infectious Diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

In addition, a comprehensive appendix is provided with each report of all Infectious Diseases partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Diseases partnering and dealmaking since 2012.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Diseases technologies and products.

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Infectious Diseases dealmaking

2.1. Introduction
2.2. Infectious Diseases partnering over the years
2.3. Infectious Diseases partnering by deal type
2.4. Infectious Diseases partnering by industry sector
2.5. Infectious Diseases partnering by stage of development
2.6. Infectious Diseases partnering by technology type
2.7. Infectious Diseases partnering by therapeutic indication

Chapter 3 - Financial deal terms for Infectious Diseases partnering

3.1. Introduction
3.2. Disclosed financials terms for Infectious Diseases partnering
3.3. Infectious Diseases partnering headline values
3.4. Infectious Diseases deal upfront payments
3.5. Infectious Diseases deal milestone payments
3.6. Infectious Diseases royalty rates

Chapter 4 - Leading Infectious Diseases deals and dealmakers

4.1. Introduction
4.2. Most active in Infectious Diseases partnering
4.3. List of most active dealmakers in Infectious Diseases
4.4. Top Infectious Diseases deals by value

Chapter 5 - Infectious Diseases contract document directory

5.1. Introduction
5.2. Infectious Diseases partnering deals where contract document available

Chapter 6 - Infectious Diseases dealmaking by therapeutic target

6.1. Introduction
6.2. Deals by Infectious Diseases therapeutic target

For more information about this report visit https://www.researchandmarkets.com/research/99jw7z/global_infectious?w=12

CONTACT: 


CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Infectious Diseases Drugs

Ads

You May Also Like

Proteostasis Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical ...

Dr. Karen Smith Joins Sucampo’s Board of Directors

ROCKVILLE, Md., July 18, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a ...